Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test aims to spot prostate cancer cells earlier

NCT ID NCT01402154

Diagnosis Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The results could help doctors decide on the best treatment approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EPISPOT blood test
What this could lead to
If successful, this could lead to a more accurate blood test to detect prostate cancer cells early, helping doctors choose the best treatment.
What could go wrong
This is a completed study comparing two detection methods, not a treatment trial. The test may not prove better than existing methods or may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

361 people

The number who actually took part.

Started

Jan 2012

Finished

Mar 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with histologically proven, localized, adenocarcinoma of the prostate who accept a curative treatment.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * Histologically proven presence of prostate adenocarcinoma * Localized disease on digital rectal examination * Cancer without extensions * Acceptance of a curative treatment by the patient Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is taking a hormone-modifying treatment * Patient taking adrogenic supplements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma of the prostate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenocarcinoma of the prostate

Contacts and locations

Locations

  • CHU de Montpellier - Hôpital Lapeyronie

    Montpellier, 34295, France

  • CHU de Montpellier - Hôpital Lapeyronie - Plateforme LCCRH

    Montpellier, 34295, France

  • CHU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, Gard, 30029, France

  • Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque

    Montpellier, 34298, France

  • Clinique Beau Soleil

    Montpellier, 34070, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.